靶向NAD免疫代谢可限制严重移植物抗宿主病并具有强效抗白血病活性
异基因造血干细胞移植后急性GVHD和肿瘤复发是主要并发症。研究发现Nampt在胃肠道GVHD患者血清及肠道T细胞中高表达,其抑制剂Fk866可减轻实验性GVHD、选择性抑制同种反应性T细胞并促进调节性T细胞稳定性,同时在小鼠白血病和移植物抗白血病模型中显著降低肿瘤负荷。GVHD患者淋巴细胞体外实验显示Fk866具有强效抗增殖作用,提示靶向NAD免疫代谢是选择性抑制同种反应性T细胞并兼具抗白血病疗效的新策略。
要点
- Nampt在胃肠道GVHD患者血清和肠道T细胞中高表达。
- Fk866抑制Nampt可减轻实验性GVHD并选择性抑制同种反应性T细胞。
- Fk866在小鼠白血病和GVL模型中显著降低肿瘤负荷。
核心结论
- 靶向NAD免疫代谢可选择性抑制急性GVHD中的同种反应性T细胞,并具有抗白血病疗效。
研究设计与样本
- 实验研究结合小鼠GVHD、白血病和移植物抗白血病模型,以及GVHD患者淋巴细胞的体外实验。
主要发现
- Nampt在胃肠道GVHD患者血清中高度升高,并在人和小鼠肠道T细胞中尤为丰富。
- Fk866强烈减轻实验性GVHD,导致T细胞亚群NAD耗竭,且不同亚群对NAD缺乏易感性不同。
- Fk866强效抑制同种反应性T细胞而非记忆T细胞的扩增,并促进FoxP3介导的调节性T细胞谱系稳定性。
- Fk866在小鼠白血病和移植物抗白血病模型中强烈降低肿瘤负荷。
- GVHD患者淋巴细胞体外实验显示Fk866具有强效抗增殖特性。
临床怎么用
- 靶向Nampt/NAD代谢可能成为选择性抑制急性GVHD同种反应性T细胞并兼顾抗白血病的新策略。
局限性
- 证据主要来自实验模型和体外实验,临床效用尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (aGVHD) and tumor relapse remain major complications after allogeneic hematopoietic stem cell transplantation. Alloreactive T cells and cancer cells share a similar metabolic phenotype to meet the bioenergetic demands necessary for cellular proliferation and effector functions. Nicotinamide adenine dinucleotide (NAD) is an essential co-factor in energy metabolism and is constantly replenished by nicotinamide phosphoribosyl-transferase (Nampt), the rate-limiting enzyme in the NAD salvage pathway. Here we show, that Nampt blockage strongly ameliorates aGVHD and limits leukemic expansion. Nampt was highly elevated in serum of patients with gastrointestinal GVHD and was particularly abundant in human and mouse intestinal T cells. Therapeutic application of the Nampt small-molecule inhibitor, Fk866, strongly attenuated experimental GVHD and caused NAD depletion in T-cell subsets, which displayed differential susceptibility to NAD shortage. Fk866 robustly inhibited expansion of alloreactive but not memory T cells and promoted FoxP3-mediated lineage stability in regulatory T cells. Furthermore, Fk866 strongly reduced the tumor burden in mouse leukemia and graft-versus-leukemia models. Ex vivo studies using lymphocytes from GVHD patients demonstrated potent antiproliferative properties of Fk866, suggesting potential clinical utility. Thus, targeting NAD immunometabolism represents a novel approach to selectively inhibit alloreactive T cells during aGVHD with additional antileukemic efficacy.
引用
- Gerner RR, Macheiner S, Reider S, et al. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity. Leukemia. 2020. PMID: 31974433. doi:10.1038/s41375-020-0709-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。